These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 38632155)

  • 1. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
    Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
    Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.
    Feld J; Belasen A; Navada SC
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):465-482. PubMed ID: 32479130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Liu L; Jia M; Sun L; Tian W; Tang P; Jiang Z
    Clin Exp Med; 2021 Nov; 21(4):537-543. PubMed ID: 33866494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes current treatment algorithm 2018.
    Steensma DP
    Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
    Battaglia MR; Cannova J; Madero-Marroquin R; Patel AA
    Curr Treat Options Oncol; 2024 Jun; 25(6):752-768. PubMed ID: 38814537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Garcia-Manero G; Chien KS; Montalban-Bravo G
    Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
    Wang C; Sallman DA
    Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
    Gener-Ricos G; Rodriguez-Sevilla JJ; Urrutia S; Bataller A; Bazinet A; Garcia-Manero G
    Leuk Lymphoma; 2024 Sep; 65(9):1233-1244. PubMed ID: 38712556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMT for Myelodysplastic Syndrome: When and Where and How.
    Jain AG; Elmariah H
    Front Oncol; 2021; 11():771614. PubMed ID: 35070975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.